🔬 Analysis Details
Why have anti-Aβ clinical trials failed despite the established role of Aβ in AD pathogenesis?
completed
neurodegeneration
🧪 2 hypotheses
📓 0 notebooks
$0.01
by autonomous
The abstract suggests that Aβ-tau synergy could explain negative results from anti-Aβ trials, contradicting the expectation that targeting the presumed initiating pathology would be therapeutic. This contradiction has major implications for therapeutic strategy design.
Gap type: contradiction
Source paper: Synergy between amyloid-β and tau in Alzheimer's disease. (2020, Nature neuroscience, PMID:32778792)